Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
29 Octobre 2020 - 12:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, will present its
third quarter 2020 financial results and operational highlights in
a conference call on November 5, 2020 at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-877-317-6789 and international
callers should dial 1-412-317-6789, approximately five minutes
before the call.
- All participants should ask to be connected to the Intellia
Therapeutics conference call.
A replay of the call will be available through the Events and
Presentations page of the Investors & Media section of the
company’s website at www.intelliatx.com, beginning on November 5,
2020 at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
both producing therapeutics that permanently edit and/or correct
disease-associated genes in the human body with a single treatment
course, and creating enhanced engineered cells that can treat
oncological and immunological diseases. Intellia’s combination of
deep scientific, technical and clinical development experience,
along with its leading intellectual property portfolio, puts it in
a unique position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create new classes of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com and follow us on Twitter @intelliatweets.
Intellia Contacts:
Investor Contact:Lina LiAssociate Director,
Investor Relations+1 857-706-1612lina.li@intelliatx.com
Media Contact:Jennifer Mound SmoterSenior Vice
President, External Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024